Indicated for: cancer
Route of administration: infusion
Substance: thiotepa (antineoplastic agent)
ATC: L01AC01 (Antineoplastic and immunomodulating agents | Alkylating agents | Ethylene imines)
This medicine may affect fertility.
Dose adjustment may be needed in liver disease.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Thiotepa is an alkylating agent used in the treatment of certain types of cancer, including bladder cancer, ovarian cancer, and breast cancer. It works by interfering with the DNA of cancer cells, thereby inhibiting their growth and division.
The medication is administered intravenously or intravesically, as directed by a doctor, and the dosage is adjusted based on the type of cancer and the patient's condition. It is primarily used as part of a chemotherapy regimen.
Patients should be closely monitored to detect potential side effects, such as bone marrow suppression, nausea, or liver toxicity. It is important for patients to inform their doctor of any unusual symptoms.
Common side effects include nausea, vomiting, decreased blood cell counts, and fatigue. In rare cases, severe reactions such as liver toxicity or serious infections may occur. Patients should be informed of these risks before starting treatment.